Outlining an iTANK Technology Platform & ELC-201 Promising Therapeutic Efficacy

Time: 9:30 am
day: Day One


  • iTANK is a technology platform that allows us to arm oncolytic virus or CAR-T cells with a pluripotent immunomodulating factor, NAP
  • Elicera’s drug candidate ELC-201 is an iTANK-engineered oncolytic virus further armed to express 4-1BBL
  • ELC-201 exhibits promising therapeutic efficacy against pancreatic cancer in murine model, and induces bystander immune activation by altering the immunosuppressive tumor microenvironment